FirstLook Lung
Blood-based cfDNA fragmentomics laboratory-developed test used as an adjunct in the lung-cancer screening pathway; not a replacement for LDCT.
- Developer
- DELFI Diagnostics
- Intended use
- Screening
- Cancer scope
- Not reported
- Specimen
- Plasma
- Molecular modality
- Fragmentomics
- Current version
- Current FirstLook Lung commercial LDT as of 2026-09
- Evidence context
- 1 structured studies · 6 indexed performance results · 2 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.